We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

AC-1204 Long-term Efficacy Response Trial (ALERT Protocol) (ALERT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01211782
Recruitment Status : Withdrawn (Study never started. Study was redesgined.)
First Posted : September 30, 2010
Last Update Posted : December 4, 2012
Information provided by (Responsible Party):

Study Description
Brief Summary:
The study will evaluate the safety & efficacy of AC-1204, a ketogenic compound, administered orally on a daily basis for 6 months. Following the 6 month double-blind phase of the study, subjects may enroll in an optional 6 month open-label extension phase. Efficacy will be evaluated by standard tests of memory and cognition, along with other measurements of activities of daily living and quality of life. Safety will be assessed by frequency of adverse events and changes in laboratory test results. Subjects will be stratified and outcomes will be separately analyzed based on apolipoprotein E4 genotype (APOE4).

Condition or disease Intervention/treatment Phase
Alzheimer's Disease Drug: caprylic triglyceride Drug: long-chain triglyceride Phase 2 Phase 3

Detailed Description:

Two primary outcome measures will be assessed in APOE4(-) patients:

  1. differences from baseline between AC-1204 and placebo groups' ADAS-cog scores at 6 months
  2. differences from baseline between AC-1204 and placebo groups' CIBIC+ scores at 6 months Secondary endpoints will include differences between AC-1204 & placebo groups' scores for these same instruments at 3 months.

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 2-3, 6-12 Month, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Subjects With Mild to Moderate Alzheimer's Disease Who Are APOE4(-)

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Experimental: AC-1204 Drug: caprylic triglyceride
oral, 20 gm, daily x 6 months
Other Name: AC-1204
Placebo Comparator: Placebo Drug: long-chain triglyceride
oral, 14 gm, daily x 6 months
Other Name: sunflower oil + maltodextrin

Outcome Measures

Primary Outcome Measures :
  1. Alzheimer's disease assessment scale - cognitive subscale (ADAS-cog) [ Time Frame: 6 months ]
    change from baseline in ADAS-cog scores at 6 months in APOE4(-) patients

Secondary Outcome Measures :
  1. Clinicians Interview Based Impression of Change with Caregiver Input (CIBIC+) [ Time Frame: 6 months ]
    change from baseline in CIBIC+ scores at 6 months in APOE4(-) patients

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   55 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Males/females between age of 55 -85 years
  • MMSE scores between 16-26
  • Probable mild to moderate AD

Exclusion Criteria:

  • Presence of other CNS disorders as alternative causes of dementia
  • Type 1 or Type 2 diabetes
  • Significant renal/hepatic disease
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01211782

United States, Florida
Meridien Research
St. Petersburg, Florida, United States, 33709
Sponsors and Collaborators
Accera, Inc.
Principal Investigator: Mildred Farmer, MD Meridien Research
More Information

Responsible Party: Accera, Inc.
ClinicalTrials.gov Identifier: NCT01211782     History of Changes
Other Study ID Numbers: AC-10-006
First Posted: September 30, 2010    Key Record Dates
Last Update Posted: December 4, 2012
Last Verified: December 2012

Keywords provided by Accera, Inc.:
Alzheimer's disease

Additional relevant MeSH terms:
Alzheimer Disease
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders